High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients
- PMID: 28407515
- DOI: 10.1016/j.leukres.2017.04.001
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients
Abstract
Overexpression of CD200, a trans-membrane protein belonging to the immunoglobulin superfamily, has been associated with poor prognosis in patients with acute myeloid leukemia (AML). As few data are available in the subset of cytogenetically-normal (CN) AML, we retrospectively evaluated the correlations between CD200 expression and response to therapy in a series of 139 adults with CN-AML. CD200 was expressed in 67/139 (48%) cases; 18 of them (28%) expressed CD200 at high intensity. No differences in CD200 expression rate were observed according to age, WBC count, type of leukemia, FLT3 or NMP1 mutation, and CD56 expression. A higher incidence of CD200 expression was observed in CD34+ cases (P<0.0001) and in BCL2+ patients (P=0.04). Complete remission (CR) was evaluable achieved in 98 patients (70%): 56/71 (79%) in CD200- and 47/67 (63%) in CD200+ patients (P=0.03), with a lower CR rate in patients with high CD200 intensity (9/18, 50%). CD200 expression had a negative impact on long-term outcome. CD200 expression, per se, did not impact on disease-free survival (DFS), but cases with high CD200 expression had a lower 3-year DFS compared to CD200-negative and low-expressing ones (0% vs 65% vs 68%, P=0.019). Three-year overall survival (OS) was 51% in CD200- and 27% in CD200+ patients (P=0.01), with a significant difference among cases with low or high CD200 expression (35% vs 0%, P=0.001). CD200 high expression defined a group with very poor DFS and OS also among the 37 FLT3-/NPM1+: 3-year DFS and OS were 88% and 60% in CD200-, 50% and 32% in CD200 low and 0% and 0% in CD200 high patients, respectively (P=0.01 for DFS and P=0.05 for OS). Our data suggest a negative impact of CD200 expression in CN-AML, with a further worsening in high-expressing cases, also in the subset of FLT3-/NPM1+ patients.
Keywords: CD200; Cytogenetically normal acute myeloid leukemia; FLT3; NPM1; Prognosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25. Hematology. 2014. PMID: 23540998
-
Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20. Int J Lab Hematol. 2017. PMID: 28318150
-
Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):274-9. doi: 10.1016/j.clml.2012.01.003. Epub 2012 Apr 4. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22481022
-
Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia.Am J Transl Res. 2020 Sep 15;12(9):4840-4852. eCollection 2020. Am J Transl Res. 2020. PMID: 33042393 Free PMC article. Review.
-
CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance.Front Oncol. 2020 Nov 26;10:584427. doi: 10.3389/fonc.2020.584427. eCollection 2020. Front Oncol. 2020. PMID: 33324560 Free PMC article. Review.
Cited by
-
Widespread use of measurable residual disease in acute myeloid leukemia practice.Leuk Res. 2018 Apr;67:92-98. doi: 10.1016/j.leukres.2018.02.006. Epub 2018 Feb 13. Leuk Res. 2018. PMID: 29482173 Free PMC article.
-
Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.Blood Adv. 2021 Sep 28;5(18):3694-3708. doi: 10.1182/bloodadvances.2020003534. Blood Adv. 2021. PMID: 34470052 Free PMC article.
-
Evaluation of CD200 marker variations and its correlation with clinicopathological features of chronic lymphocytic leukemia patients: a case-control study.J Hematop. 2025 Jul 1;18(1):28. doi: 10.1007/s12308-025-00643-9. J Hematop. 2025. PMID: 40593283
-
CD200:CD200R Interactions and Their Importance in Immunoregulation.Int J Mol Sci. 2021 Feb 5;22(4):1602. doi: 10.3390/ijms22041602. Int J Mol Sci. 2021. PMID: 33562512 Free PMC article. Review.
-
Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients.Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2225-2230. doi: 10.31557/APJCP.2020.21.8.2225. Asian Pac J Cancer Prev. 2020. PMID: 32856848 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous